alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
#### Kimiko RANSOME, Plaintiff-Appellant, v. L. LONGERO, Correctional Officer; et al., Defendants-Appellees.

No. 12-15516.

United States Court of Appeals, Ninth Circuit.

Submitted Dec. 19, 2012.*

Jan. 3, 2013.

Kimiko Ransome, Chowchilla, CA, pro se.

Before: GOODWIN, WALLACE, and FISHER, Circuit Judges.

*

 The panel unanimously concludes this case is suitable for decision without oral argument. *See*Fed. R.App. P. 34(a)(2).

MEMORANDUM ***

California state prisoner Kimiko Ran-some appeals pro se from the district court’s judgment dismissing sua sponte her 42 U.S.C. § 1983 action for failure to exhaust administrative remedies under the Prison Litigation Reform Act (“PLRA”), 42 U.S.C. § 1997e(a). We have jurisdiction under 28 U.S.C. § 1291. We review de novo the district court’s dismissal for failure to exhaust administrative remedies. *Wyatt v. Terhune,*315 F.3d 1108, 1117 (9th Cir.2003). We vacate and remand.

Dismissal before defendant’s appearance in the case was improper because Ran-some alleged in her complaint that she had completed the prison grievance process and exhausted her available administrative-remedies prior to filing suit. *See Jones v. Bock,*549 U.S. 199, 214-16, 127 S.Ct. 910, 166 L.Ed.2d 798 (2007) (exhaustion is an affirmative defense and sua sponte dismissal for failure to exhaust administrative remedies under the PLRA is only appropriate if, taking the prisoner’s factual allegations as true, the complaint establishes her failure to exhaust).

VACATED and REMANDED.

***

 This disposition is not appropriate for publication and is not precedent except as provided by 9 th Cir. R. 36-3.
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Energy

###### Federal Energy Regulatory Commission

          - [Project No. 6550-004]

                    1. By letter filed June 23, 2017, Stephen J. Bores informed the Commission that the exemption from licensing for the Biber-Spellenberg Hydro Project No. 6550, originally issued February 14, 1983 [1]                                          has been transferred to JBS Rentals, LLC. The project is located on Bidden Creek in Trinity County, California. The transfer of an exemption does not require Commission approval.                

2. JBS Rentals, LLC is now the exemptee of the Biber-Spellenberg Project No. 6550. All correspondence should be forwarded to: Mr. Jeremy Brown, Owner, P.O. Box 1233, Willow Creek, CA 95573, Phone 530-629-3100.

Dated: August 15, 2017.

Kimberly D. Bose,

Secretary.

# Footnotes

1.                             Order Granting Exemption from Licensing of a Small Hydroelectric Project of 5 MW or Less.                         *Frank M. Biber and Steven Spellenberg,*                         22 FERC ¶ 62,182 (1983).                    
        Back to Citation      

[FR Doc. 2017-17557 Filed 8-18-17; 8:45 am]

 BILLING CODE 6717-01-P
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Health and Human Services

###### National Institutes of Health

      ( print page 36730)    
                    Notice is hereby given of a change in the meeting of the Center for Scientific Review Special Emphasis Panel, July 28, 2009, 11 a.m. to July 28, 2009, 3 p.m., National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD, 20892 which was published in the                     **Federal Register**                     on June 26, 2009, 74 FR 30595-30596.                

This meeting will be an AED held on July 27, 2009, 9 a.m. to July 28, 2009, 11:55 p.m. The meeting location remains the same. The meeting is closed to the public.

Dated: July 20, 2009.

Jennifer Spaeth,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. E9-17738 Filed 7-23-09; 8:45 am]

BILLING CODE 4140-01-P
---

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF
2002

The undersigned, Bondy Tan, hereby certifies, pursuant to 18
U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley
Act of 2002, that:

|(1) | the annual report on Form 10-K of Lightscape Technologies
      Inc. for the year ended March 31, 2009 (the Report) fully complies with
      the requirements of Section 13(a) or 15(d) of the Securities Exchange Act
      of 1934; and
|--- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|    |                                                                                                                                                                                                                                             
|(2) | the information contained in the Report fairly presents,
      in all material respects, the financial condition and results of
      operations of Lightscape Technologies Inc.                                                            

Dated: July 14, 2009



/s/ Bondy TanBondy Tan President and Chief Executive Officer (Principal
Executive Officer, Principal Financial Officer and Principal Accounting Officer)

A signed original of this written statement required by Section
906, or other document authenticating, acknowledging, or otherwise adopting the
signature that appears in typed form within the electronic version of this
written statement required by Section 906, has been provided to Lightscape
Technologies Inc. and will be retained by Lightscape Technologies Inc. and
furnished to the Securities and Exchange Commission or its staff upon request.

---
EXHIBIT 32

CERTIFICATION
REQUIRED UNDER SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In
connection with the filing of the financial statements of Ophthalmic Imaging Systems
(Registrant) for the quarter ended June 30, 2007 (the Report),
each of the undersigned hereby certifies, to such officers knowledge, that:

|1. | The Report fully complies with the requirements of section 13(a) or 15(d) of the
          Securities Exchange Act of 1934, as amended, and
|-- | -------------------------------------------------------------------------------------------------------------------------------------------

|2. | The information contained in the Report fairly presents, in all material
          respects, the financial condition and results of operations of Registrant.
|-- | -------------------------------------------------------------------------------------------------------------------------------------------------------------

Date: August 7,
2007

| |                        
| | -----------------------
| | /s/ Gil Allon          
| |                        
| | Gil Allon              
| | Chief Executive Officer
| |                        
| | /s/ Ariel Shenhar      
| |                        
| | Ariel Shenhar          
| | Chief Financial Officer
No. 918.

#### Lynch et al. *v.*New Jersey et al.

May 13, 1946.

Petition for certiorari dismissed on motion of counsel for petitioners.

*Samuel L. Rothbard*for petitioners.

On petition for writ of certiorari to the Court of Errors and Appeals of New Jersey.
No. 1013.

No. 1014.

No. 1015.

#### Hare *v.*United States; Hare *v.*United States ; and Hare *v.*United States.

April 29, 1946.

*Daniel S. Ring*and *C. Leo DeOrsey*for petitioners.

*Solicitor General Mc-Grath, Robert S. Erdahl*and *Beatrice Rosenberg*for the United States.

Petition for writs of certiorari to the Circuit Court of Appeals for the Seventh Circuit denied.
[Federal Register Volume 82, Number 156 (Tuesday, August 15, 2017)]
[Notices]
[Pages 38722-38723]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-17316]


=======================================================================
-----------------------------------------------------------------------

OVERSEAS PRIVATE INVESTMENT CORPORATION


Sunshine Notice--September 6, 2017 Public Hearing

TIME AND DATE: 2:00 p.m., Wednesday, September 6, 2017.

PLACE: Offices of the Corporation, Twelfth Floor Board Room, 1100 New 
York Avenue NW., Washington, DC.

STATUS: Hearing OPEN to the Public at 2:00 p.m.

PURPOSE: Public Hearing in conjunction with each meeting of OPIC's 
Board of Directors, to afford an opportunity for any person to present 
views regarding the activities of the Corporation.

PROCEDURES: Individuals wishing to address the hearing orally must 
provide advance notice to OPIC's Corporate Secretary no later than 5 
p.m. Wednesday, August 30, 2017. The notice must include the 
individual's name, title, organization, address, and telephone number, 
and a concise summary of the subject matter to be presented.

[[Page 38723]]

    Oral presentations may not exceed ten (10) minutes. The time for 
individual presentations may be reduced proportionately, if necessary, 
to afford all participants who have submitted a timely request an 
opportunity to be heard.
    Participants wishing to submit a written statement for the record 
must submit a copy of such statement to OPIC's Corporate Secretary no 
later than 5 p.m. Wednesday, August 30, 2017. Such statement must be 
typewritten, double spaced, and may not exceed twenty-five (25) pages.
    Upon receipt of the required notice, OPIC will prepare an agenda, 
which will be available at the hearing, that identifies speakers, the 
subject on which each participant will speak, and the time allotted for 
each presentation.
    A written summary of the hearing will be compiled, and such summary 
will be made available, upon written request to OPIC's Corporate 
Secretary, at the cost of reproduction.
    Written summaries of the projects to be presented at the September 
14, 2017, Board meeting will be posted on OPIC's Web site.

CONTACT PERSON FOR INFORMATION:  Information on the hearing may be 
obtained from Catherine F.I. Andrade at (202) 336-8768, via facsimile 
at (202) 408-0297, or via email at <a href="/cdn-cgi/l/email-protection#5d1e3c2935382f343338731c33392f3c39381d322d343e733a322b"><span class="__cf_email__" data-cfemail="01426075696473686f642f406f6573606564416e7168622f666e77">[email protected]</span></a>.

    Dated: August 11, 2017.
Catherine F.I. Andrade,
OPIC Corporate Secretary.
[FR Doc. 2017-17316 Filed 8-11-17; 4:15 pm]
 BILLING CODE 3210-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>
[Federal Register Volume 82, Number 159 (Friday, August 18, 2017)]
[Notices]
[Page 39444]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-17427]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Center for Advancing Translational Sciences; Notice of 
Closed Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The contract proposals and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the contract proposals, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Center for Advancing Translational 
Sciences Special Emphasis Panel Contract Review.
    Date: September 12, 2017.
    Time: 1:00 p.m. to 4:00 p.m.
    Agenda: To review and evaluate contract proposals.
    Place: National Institutes of Health, One Democracy Plaza, Room 
1037, 6701 Democracy Boulevard, Bethesda, MD 20892, (Telephone 
Conference Call).
    Contact Person: Rahat (Rani) Khan, Ph.D., Scientific Review 
Officer, Office of Scientific Review, National Center for Advancing, 
Translational Sciences, 6701 Democracy Blvd., Rm 1078, Bethesda, MD 
20892, 301-894-7319, <a href="/cdn-cgi/l/email-protection#543f3c353a2666143727267a3a3d3c7a333b22"><span class="__cf_email__" data-cfemail="6c07040d021e5e2c0f1f1e42020504420b031a">[email protected]</span></a>.

(Catalogue of Federal Domestic Assistance Program Nos. 93.859, 
Pharmacology, Physiology, and Biological Chemistry Research; 93.350, 
B--Cooperative Agreements; 93.859, Biomedical Research and Research 
Training, National Institutes of Health, HHS)


    Dated: August 14, 2017.
David Clary,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2017-17427 Filed 8-17-17; 8:45 am]
BILLING CODE 4140-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>
**Exhibit
      32.1**








**CERTIFICATION
      OF CHIEF EXECUTIVE OFFICER**


**PURSUANT
      TO 18 U.S.C. SECTION 1350,**


**AS
      ADOPTED PURSUANT TO**


**SECTION
      906 OF THE SARBANES-OXLEY ACT OF 2002**





In
      connection with the annual report of Wilshire Enterprises, Inc. (the "Company")
      on Form 10-K for the year ended December 31, 2005 (the "Report"), I, S. Wilzig
      Izak, Chief Executive Officer of the Company, do hereby certify, pursuant to
      18
      U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley
      Act of 2002, that to my knowledge:





(1)
      The
      Report fully complies with the requirements of Section 13(a) or 15(d) of the
      Securities Exchange Act of 1934, 15 U.S.C. Section 78m(a) or 78o(d); and





(2)
      The
      information contained in the Report fairly presents, in all material respects,
      the consolidated financial condition and results of operations of the Company.





Dated:
      March 31, 2006





By: /s/
      S.
      Wilzig Izak


S.
      Wilzig
      Izak


Chief
      Executive Officer
EXHIBIT 32.1**SECTION 1350 CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER**In connection with the Annual Report of The Washington Post Company (the “Company”) on Form 10-Kfor the fiscal year ended January 1, 2006 (the “Report”), I, Donald E. Graham, Chief ExecutiveOfficer (principal executive officer) of the Company, certify, pursuant to 18 U.S.C. § 1350, asadopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that: (1) The Report fully complies with the requirements of Section 13(a) or 15(d) of theSecurities Exchange Act of 1934; and  (2) The information contained in the Report fairly presents, in all material aspects,the financial condition and results of operations of the Company.        Date: March 3, 2006 /s/  Donald E. Graham   Donald E. Graham,   Chief Executive Officer
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Justice

###### Antitrust Division

                    Notice is hereby given that, on July 11, 2017, pursuant to section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301*et seq.*                     (“the Act”), Network Centric Operations Industry Consortium, Inc. (“NCOIC”) has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing changes in its membership. The notifications were filed for the purpose of extending the Act's provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Specifically, Lewis Combs (individual member), Cincinnati, OH, has been added as a party to this venture.                

Also, Tata Power SED, Mumbai, INDIA; and beamSmart, Vienna, VA, have withdrawn as parties to this venture.

No other changes have been made in either the membership or planned activity of the group research project. Membership in this group research project remains open, and NCOIC intends to file additional written notifications disclosing all changes in membership.

                    On November 19, 2004, NCOIC filed its original notification pursuant to section 6(a) of the Act. The Department of Justice published a notice in the                     **Federal Register**                     pursuant to section 6(b) of the Act on February 2, 2005 (70 FR 5486).                

                    The last notification was filed with the Department on March 13, 2017. A notice was published in the                     **Federal Register**                     pursuant to section 6(b) of the Act on April 4, 2017 (82 FR 16420).                

Patricia A. Brink,

Director of Civil Enforcement, Antitrust Division.

[FR Doc. 2017-17150 Filed 8-14-17; 8:45 am]

BILLING CODE P
IN THE SUPREME COURT OF PENNSYLVANIA

In the Matter of

LISA MARIE RICHFORD

PETITION FOR REINSTATEMENT
FROM RETIRED STATUS :

:

:

:

:

:

: No. 156 DB 201 9 (No. 86 RST 2019)

Attorney Registration No. 67337

( Out of State )

O R D E R

PER CURIAM

AND NOW , this 9 th day of October

, 201 9 , the Report and Recommendation of

Disciplinary Board Member dated October 1, 2019

, is approved and it is ORDERED that

Lisa Marie Richford

, who has been on Retired Status

, has never been suspended or

disbarred, and has demonstrated that s he has the moral qualifications, competency and

learning in law required for admission to practice in the Commonwealth, shall be and is,

hereby reinstated to active status as a member of th e Bar of this Commonwealth. The

expenses incurred by the Board in the investigation and processing of this matter shall

be paid by the Petitioner.
Exhibit 31.1
**CERTIFICATIONS**
I, Michael J. Astrue, certify that:
1. I have reviewed this Quarterly Report on Form 10-Q of TranskaryoticTherapies, Inc.; 2. Based on my knowledge, this report does not contain any untrue statementof a material fact or omit to state a material fact necessary to make thestatements made, in light of the circumstances under which such statementswere made, not misleading with respect to the period covered by thisreport; 3. Based on my knowledge, the financial statements, and other financialinformation included in this report, fairly present in all materialrespects the financial condition, results of operations and cash flows ofthe registrant as of, and for, the periods presented in this report; 4. The registrant’s other certifying officer and I are responsible forestablishing and maintaining disclosure controls and procedures (asdefined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrantand have:
a) Designed such disclosure controls and procedures, or causedsuch disclosure controls and procedures to be designed under oursupervision, to ensure that material information relating to theregistrant, including its consolidated subsidiaries, is made known tous by others within those entities, particularly during the period inwhich this report is being prepared; b) [Paragraph omitted in accordance with SEC transitioninstructions contained in SEC Release 34-47986] c) Evaluated the effectiveness of the registrant’s disclosurecontrols and procedures and presented in this report our conclusionsabout the effectiveness of the disclosure controls and procedures, asof the end of the period covered by this report based on suchevaluation; and d) Disclosed in this report any change in the registrant’sinternal control over financial reporting that occurred during theregistrant’s most recent fiscal quarter (the registrant’s fourthfiscal quarter in the case of an annual report) that has materiallyaffected, or is reasonably likely to materially affect, theregistrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer and I have disclosed, based onour most recent evaluation of internal control over financial reporting,to the registrant’s auditors and the audit committee of the registrant’sboard of directors (or persons performing the equivalent functions):
a) All significant deficiencies and material weaknesses in thedesign or operation of internal control over financial reportingwhich are reasonably likely to adversely affect the registrant’sability to record, process, summarize and report financialinformation; and b) Any fraud, whether or not material, that involves management orother employees who have a significant role in the registrant’sinternal control over financial reporting.   Date: August 9, 2004 /s/ Michael J. Astrue   Michael J. Astrue President and Chief Executive Officer (Principal Executive Officer)
45
# msd_CD_R2_00_2020
Exhibit
23








CONSENT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM





We
consent to the incorporation by reference in Registration Statement Nos.
333-151119 on Form S-3, and 333-127889-01, 333-71990-01 and 333-63101-01 on Form
S-8 of our reports dated February 25, 2010, relating to the consolidated
financial statements and financial statement schedule of Wisconsin Public
Service Corporation and subsidiary, and the effectiveness of Wisconsin Public
Service Corporation’s internal control over financial reporting, appearing in
this Annual Report on Form 10-K of Wisconsin Public Service Corporation for the
year ended December 31, 2009.








/s/ Deloitte &
Touche LLP











Milwaukee,
Wisconsin


February 25,
2010